Orexigen Therapeutics posts $1.45 million operating loss for February

By Caroline Salls

Pittsburgh, April 2 – Orexigen Therapeutics, Inc. reported a $1.45 million loss from operations for February on zero net product sales, according to its monthly operating report filed Tuesday with the Securities and Exchange Commission.

Those figures are the same as the ones reported for January, as is the $3.65 million February net loss.

The company had $25.9 million in cash and cash equivalents as of Feb. 28, down from $26.47 million at the end of January.

Orexigen is a San Diego-based biopharmaceutical company focused on the treatment of obesity. The company filed for bankruptcy on March 12, 2018 in the U.S. Bankruptcy Court for the District of Delaware under Chapter 11 case number 18-10518.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.